VHL disease.

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Von Hippel-Lindau (VHL) disease is a genetic disorder associated with an increased risk of various tumors, including renal cell carcinoma, central nervous system hemangioblastomas, and pheochromocytomas.
• The VHL gene product is crucial in regulating cellular response to hypoxia by targeting hypoxia-inducible factor (HIF) for degradation.

Purpose of the Study:

• To review the clinical manifestations of VHL disease, with a specific focus on its pediatric aspects.
• To explore the emerging understanding of VHL's HIF-independent functions and their contribution to the disease's complex phenotype.
• To discuss the translational implications of these findings for future therapeutic strategies.

Main Methods:

• This is a review article, synthesizing existing clinical and research data.
• Analysis of genotype-phenotype correlations, particularly concerning pheochromocytoma risk.
• Examination of recent research on the pleiotropic roles of the VHL gene.

Main Results:

• VHL disease presents unique challenges and features in the pediatric population.
• Genotype-phenotype studies suggest VHL has functions beyond HIF regulation, impacting disease presentation.
• Emerging research is uncovering novel, HIF-independent roles of VHL.

Conclusions:

• Understanding the multifaceted roles of VHL is critical for comprehending the full spectrum of VHL disease.
• Further research into HIF-independent VHL functions holds promise for developing novel therapeutic interventions.
• These advancements offer potential for improved patient outcomes in VHL disease.